A Phase I study of alvespimycin 3
INTRODUCTION
The molecular chaperone HSP90 ensures correct folding and function of numerous client proteins [1] [2] [3] [4] including the androgen receptor and oncogenic kinases such as BRAF (for an up to date list visit website of Dr Didier Picard *). HSP90 inhibition targets client proteins for proteasomal destruction [3] . The resulting combined effect on multiple oncogenic client proteins, their associated biochemical pathways, and hallmark cancer traits [5] forms the basis for the observed anticancer activity [6] [7] [8] [9] [10] .
HSP90 inhibition results in a well-characterized, mechanism-based change in expression of specific proteins [11, 12] . Depletion of client proteins (e.g. CDK4, ERBB2 or LCK) together with induction of certain heat shock proteins (e.g. HSP72, the inducible isoform of HSP70) constitute a molecular signature of HSP90 inhibition that can be measured as a pharmacodynamic endpoint [13] [14] [15] .
The HSP90 inhibitor alvespimycin (17-dimethylaminoethylamino-17-demethoxygeldanamycin; 17-DMAG) exhibits reduced metabolic liability, lower plasma protein binding, increased water solubility higher oral bioavailability and superior antitumor activity compared to tanespimycin (17-allylamino-17-demethoxy geldanamycin; 17-AAG), the first HSP90 inhibitor in clinical trials [10] .
Selectivity of HSP90 inhibitors for tumor over normal tissue was demonstrated [6, 16] and, like 17-AAG, 17-DMAG is retained longer in tumor than in normal tissue [17] .
We postulated that obtaining a biologically effective dose (BED) lower than the MTD may be possible .
*http://www.picard.ch/downloads/Hsp90interactors.pdf.
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The primary objective was evaluation of drug safety and recommendation of a phase II dose. Secondary objectives were to investigate the pharmacokinetic and pharmacodynamic properties, define a BED and evaluate tumor response.
Other phase I studies of 17-DMAG performed concurrently utilized different schedules and administration routes [18] [19] [20] . Pre-clinical studies confirmed anticancer activity of 17-DMAG using a variety of dosing schedules [8] . We proposed a weekly schedule also based on experience with 17-AAG, for which weekly administration was convenient, deliverable with manageable toxicity and showed potential clinical activity whereas schedules with increased dosing frequency (e.g. daily) were more toxic [21, 22] . This present study is to our knowledge the only one to incorporate pharmacodynamic assays validated before patient accrual [23] [24] [25] .
Additionally, the 3+3 design facilitated investigation of the pharmacokinetic profile of 17-DMAG and evidence of target inhibition was obtained.
PATIENTS AND METHODS

Study design
A phase I trial of weekly IV 17-DMAG was performed with dose escalation (to determine MTD) and planned subsequent dose de-escalation (to define a BED).
The starting dose was 2.5 mg/m 2 , approximately 1/10 th the dose lethal (LD 10 ) to dogs 7 associated fever; platelet count < 25x10 9 /l; any other non-hematological toxicity (≥ Grade 3) except nausea, vomiting, diarrhea, rash, arthralgia or myalgia without appropriate prophylactic measures or alopecia (grade 1 or 2); or toxicity that prevented completion of 4 weeks 17-DMAG treatment. Patients who did not complete four weeks 17-DMAG for reasons other than toxicity were replaced.
Cohorts of three patients were entered and dose doubling performed until ≥ Grade 2 toxicity occurred. Further dose escalations were limited to 50%, in event of Grade 2 toxicity or 33% following ≥ Grade 3 toxicity.
After observing DLT, the cohort increased to 6 patients maximum. The maximum administered dose (MAD) was that at which ≥ 2/6 patients experienced DLT. The MTD was the previous dose level tested at which ≤ 1/6 patients experienced DLT.
The first patient at each dose level completed two weeks of 17-DMAG prior to other patients being treated. No delay was mandated between treating the second and subsequent patients.
Pre and post 17-DMAG tumor biopsies were planned. Once MTD was determined, additional patients with biopsiable disease were entered, initially at MTD level, to yield five, paired, pre and post dose biopsies per dose cohort. Detection of HSP90 inhibition (HSP72 induction with either CDK4 and/or ERBB2 depletion) in tumor from ≥ 4/5 patients allowed dose de-escalation to the prior dose level. A BED was defined as the lowest dose at which the HSP90 inhibition was detected in tumor samples from ≥ 4/5 patients.
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Inclusion and exclusion criteria
Patients, aged ≥ 18 years, with histologically/cytologically confirmed solid tumors refractory to available therapy were entered. Prior treatment, radiotherapy (except for palliative reasons), endocrine therapy, immunotherapy or chemotherapy, was completed at least four weeks (six weeks for nitrosoureas and mitomycin-C) prior to 17-DMAG. All toxic manifestations of previous treatments had resolved ( Tumor biopsy results were verified by two blinded, experienced assessors. Additional quantification was performed, although not externally validated, using ImageQuant TM software and protein levels were normalized to corresponding GAPDH control. 
Characterization of response
Tumors were assessed before 17-DMAG and eight weekly using RECIST criteria confirmed with repeat measurements not less than four weeks apart and were reviewed by an independent clinician and radiologist.
RESULTS
Demographics
Between February 2006 and April 2008, 25 patients were recruited to the study and all received at least one 17-DMAG dose ( Table 1 ). The male: female ratio was 14:11, with median age of 58 (range 38-78) years. Malignant melanoma (7/25) was the commonest histological subtype. All patients had an ECOG performance status of 0 or 1.
Dose escalation and de-escalation
The starting dose was 2. Research. Table 3 Table 2 ).
Pharmacokinetics of 17-DMAG
Research. A patient with metastatic melanoma, treated at 40mg/m 2 , had a partial response (PR) and was on treatment for 159 weeks before PD ( Figure 4B ). Prior treatment was adjuvant interferon, followed by combination chemotherapy (dacarbazine and sorafenib) on diagnosis of metastases. Progression of known intra-pulmonary and lymph node metastasis preceded trial entry.
Discussion
The MTD of weekly 17-DMAG was 80 mg/m 2 IV. Nausea, vomiting, fatigue and
Research. (1), radical radiotherapy (2), LHRH antagonist (3), bicalutamide withdrawal (4) and starting 17-DMAG (5), PSA and CT confirmed CR (6) and progression of disease (7). B). CT scans from a patient with metastatic melanoma at commencement of study and 30 months after starting 17-DMAG. Prior therapy had been adjuvant interferon and combination chemotherapy with dacarbazine and sorafenib. Patient received 159 weeks of 17-DMAG prior to PD. 
on 
